Sinew Pharma (ROCO:6634) EPS (Basic): NT$-1.66 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6634 Sinew Pharma Inc ROCO:6634
25 GF Score
Price NT$60.10
! 2 Warning Signs
View Full Analysis

What is Sinew Pharma EPS (Basic)?

Sinew Pharma ROCO:6634 +0.17% 25 EPS (Basic) is NT$-1.66 as of Jun. 2026. GuruFocus rates ROCO:6634 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

Sinew Pharma's basic earnings per share (Basic EPS) for the six months ended in Jun. 2026 was NT$-0.84. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-1.66.

Sinew Pharma's EPS (Diluted) for the six months ended in Jun. 2026 was NT$-0.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-1.66.

Sinew Pharma's EPS without NRI for the six months ended in Jun. 2026 was NT$-0.84. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was -1.66.

During the past 3 years, the average EPS without NRI Growth Rate was 4.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Sinew Pharma's highest 3-Year average EPS without NRI Growth Rate was 7.40% per year. The lowest was -13.80% per year. And the median was 1.85% per year.

Sinew Pharma  (ROCO:6634) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sinew Pharma EPS (Basic) Related Terms

Sinew Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Sinew Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinew Pharma EPS (Basic) Chart

Sinew Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.54 -2.02 -2.43 -2.11 -1.74

Sinew Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.04 -1.07 -0.92 -0.82 -0.84
ROCO:6634
25GF Score
Sinew Pharma Inc ROCO:6634
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinew Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sinew Pharma's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-123.745-0)/71.051
=-1.74

Sinew Pharma's Basic EPS for the quarter that ended in Jun. 2026 is calculated as

Basic EPS (Q: Jun. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-60.096-0)/71.289
=-0.84

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-1.66 mean?
Sinew Pharma (ROCO:6634) has a EPS (Basic) of NT$-1.66 as of Jun. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sinew Pharma and its competitors.
Is Sinew Pharma's EPS (Basic) too high?
Sinew Pharma's current EPS (Basic) is NT$-1.66. Overall, Sinew Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Sinew Pharma's EPS (Basic) compare to VRTX and REGN?
Sinew Pharma's EPS (Basic) of NT$-1.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sinew Pharma and its competitors. Sinew Pharma's current EPS (Basic) is NT$-1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinew Pharma stock overvalued right now?
Sinew Pharma (ROCO:6634) has a current EPS (Basic) of NT$-1.66. The current EPS (Basic) is NT$-1.66. Sinew Pharma's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Sinew Pharma (ROCO:6634), the current EPS (Basic) is NT$-1.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinew Pharma Business Description

Address Xueyin Road, Lane 130, Section 1, C516, Building C, Number 99, Nangang District, Taipei, TWN, 11571
Sinew Pharma Inc is a Taiwan-based biopharmaceutical company. The company is mainly engaged in the research and development of new drugs for the treatment of liver diseases and pain relief. Its drug candidates includes SNP-610, SNP-630, SNP-810, SNP-820, SNP-830 and SNP-840.
25GF Score

Get the complete analysis for ROCO:6634

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$60.10
Price